The PCAIs constitute a novel group of anticancer agents designed to treat cancers driven primarily by KRAS and related proteins or those that rely on them as resistance genotypes, such as the drug-resistant forms of breast cancer that are the subject of the present study. Here, KRAS is linked to breast cancer.